ストックスクリーナーアプリを入手
42.23
2.44%
1.005
前日終値:
$41.22
開ける：
$41.46
24時間の取引高:
212.80K
Relative Volume:
0.10
時価総額：
$7.08B
収益：
$1.56B
当期純損益:
$152.72M
株価収益率:
46.95
EPS:
0.8994
ネットキャッシュフロー:
$221.80M
1週間 パフォーマンス:
+4.88%
1か月 パフォーマンス:
-2.68%
6か月 パフォーマンス:
+22.28%
1年 パフォーマンス:
+39.54%
1日の値動き範囲:
$41.35
$42.29
1週間の範囲:
$38.98
$41.57
52週間の値動き範囲:
$27.00
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
42.23 | 7.08B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
19.74 | 63.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.65 | 48.57B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.91 | 23.24B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-13 | 再開されました | JP Morgan | Neutral |
| 2026-06-29 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS) - Yahoo Finance
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Form 8K Alkermes plc. For: 21 September By Investing.com - Investing.com Canada
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - Stock Titan
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - PA Media
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise (NASDAQ:ALKS) - Seeking Alpha
Alkermes upgraded to Buy on strong growth, new drug launches, and promising pipeline in CNS disorders. - Pluang
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Business Wire
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Responsive Playbooks and the ALKS Inflection - Stock Traders Daily
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com Australia
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com India
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Motley Fool
Alkermes Executive Sells 7,576 Shares, Reducing Holdings - Intellectia AI
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - Law360
Rising Star: Goodwin's Heath Ingram - Law360
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Canada
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 - Yahoo Finance
Alkermes’ investigational narcolepsy treatment improved wakefulness at every dose - Stock Titan
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
Alkermes Plc (ALKS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gaffin David Joseph | Officer |
Oct 02 '26 |
Proposed Sale |
41.03 |
2,034 |
83,455 |
0 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. |
Sep 03 '26 |
Sale |
48.01 |
2,034 |
97,652 |
223,422 |
| Gaffin David Joseph | Officer |
Sep 03 '26 |
Proposed Sale |
48.01 |
2,034 |
97,652 |
0 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Sep 01 '26 |
Option Exercise |
24.59 |
5,000 |
122,950 |
74,389 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Sep 01 '26 |
Sale |
46.99 |
9,000 |
422,874 |
65,389 |
| Hopkinson Craig C. | Officer |
Sep 01 '26 |
Proposed Sale |
46.99 |
9,000 |
422,874 |
0 |
| Nichols Christian Todd | SVP, Chief Commercial Officer |
Aug 17 '26 |
Sale |
49.23 |
7,576 |
372,937 |
102,193 |
| Nichols Christian Todd | Officer |
Aug 17 '26 |
Proposed Sale |
49.23 |
7,576 |
372,937 |
0 |
| snyderman nancy lynn MD | Director |
Aug 03 '26 |
Option Exercise |
46.72 |
44,472 |
2,077,732 |
59,867 |
| snyderman nancy lynn MD | Director |
Aug 03 '26 |
Sale |
50.35 |
44,472 |
2,239,076 |
15,395 |
0.10%
0.29%
大文字化:
|
ボリューム (24 時間):